Targeting miR-9 in gastric cancer cells using locked nucleic acid oligonucleotides by Joana Filipa Lima et al.
Lima et al. BMC Molecular Biol  (2018) 19:6  
https://doi.org/10.1186/s12867-018-0107-6
RESEARCH ARTICLE
Targeting miR-9 in gastric cancer cells 
using locked nucleic acid oligonucleotides
Joana Filipa Lima1,2,3,4* , Joana Carvalho3,4, Inês Pinto‑Ribeiro4,5, Carina Almeida6, Jesper Wengel7, 
Laura Cerqueira1,2, Céu Figueiredo3,4,5, Carla Oliveira3,4,5† and Nuno Filipe Azevedo1†
Abstract 
Background: Gastric cancer is the third leading cause of cancer‑related mortality worldwide. Recently, it has been 
demonstrated that gastric cancer cells display a specific miRNA expression profile, with increasing evidence of the 
role of miRNA‑9 in this disease. miRNA‑9 upregulation has been shown to influence the expression of E‑cadherin‑
encoding gene, triggering cell motility and invasiveness.
Results: In this study, we designed LNA anti‑miRNA oligonucleotides with a complementary sequence to miRNA‑9 
and tested their properties to both detect and silence the target miRNA. We could identify and visualize the in vitro 
uptake of low‑dosing LNA‑based anti‑miRNA oligonucleotides without any carrier or transfection agent, as early as 
2 h after the addition of the oligonucleotide sequence to the culture medium. Furthermore, we were able to assess 
the silencing potential of miRNA‑9, using different LNA anti‑miRNA oligonucleotide designs, and to observe its subse‑
quent effect on E‑cadherin expression.
Conclusions: The administration of anti‑miRNA sequences even at low‑doses, rapidly repressed the target miRNA, 
and influenced the expression of E‑cadherin by significantly increasing its levels.
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Background
Gastric cancer (GC) is responsible for nearly 1 million 
deaths per year worldwide [1]. Like other cancers, the 
development of GC is a multistep process where the 
accumulation of genetic and epigenetic changes occurs 
[2]. E-cadherin inactivation is the most well-established 
defect in GC [3, 4]. In hereditary diffuse-type of GC and 
in sporadic GC with a diffuse component, the mecha-
nisms that contribute to E-cadherin impairment are asso-
ciated mostly with intragenic mutations, CDH1 locus 
deletions and promoter methylation, representing almost 
50% of the cases. However, E-cadherin protein expression 
occurs in most GCs of both diffuse and intestinal type, 
so other mechanisms may occur to explain the overall 
defects on E-cadherin expression, such as miRNA post-
transcriptional regulation.
MicroRNAs (miRNAs) are small, single-stranded and 
non-coding RNAs, with approximately 21 nucleotides 
that regulate gene expression at a posttranscriptional 
level [5–7]. They complementarily bind to the 3′UTR of 
their target mRNAs causing their degradation, transla-
tional repression, and/or deadenylation [8]. Upregulated 
miRNAs are often associated with protein downregu-
lation being implicated in cancer and often displaying 
oncogenic activity [9–14]. Several studies have demon-
strated that miR-9 is significantly upregulated in breast, 
liver, and colorectal cancer [15–20]. Our analysis of the 
miRNA profile of 37 cancer and 4 normal gastric tissue 
specimens, has also confirmed that miR-9 was overex-
pressed in gastric cancer tissues [4]. MiR-9 was shown to 
be responsible for the negative regulation of the CDH1 
gene, leading to tumor progression and invasiveness [21].
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The targeting of aberrant miRNAs with antisense oligo-
nucleotides (AMOs) has been put forward as a promising 
approach for post-transcriptional gene control in cancer 
therapy [22]. AMOs can act as competitive inhibitors 
of miRNAs, impairing their ability to interact with and 
repress cellular target mRNAs [23–31]. Locked Nucleic 
Acid (LNA) oligonucleotides are being used as AMOs 
due to their increased thermal stability and improved 
selective power with respect to their nucleic acid targets 
[23–27] to detect and to silence aberrant miRNAs in sev-
eral human diseases, including cancer. Furthermore, they 
show low toxicity effects, being prone to be used in vivo 
for in situ localization of miRNAs in cells and tissues [27, 
28].
In this work, we pursued an approach that enables 
miRNA antagonism in GC using nucleic acid mimics 
(Fig. 1). Our main goal was to design AMOs capable of 
detecting and silencing miR-9, with the aim of reestab-
lishing E-cadherin expression, using the model of GC 
as a proof-of-concept. For that, two LNA-based AMOs 
with a complementary sequence to miR-9 were designed, 
their cellular uptake and cytotoxicity assessed, and their 
effects on the expression of miR-9 and of E-cadherin 
determined.
Methods
Cell lines and culture conditions
Human gastric cancer cell line MKN74 was purchased 
from the Japanese Collection of Research Bioresources 
Cell Bank (JCRB025, JCRB Cell Bank, Tokyo, Japan). 
HeLa (ATCC ® CCL-2™, derived from human cervix car-
cinoma) and human embryonic kidney 293 (HEK293, 
ATCC ® CRL-1573™) cell lines were purchased from 
the American Type Culture Collection (ATCC ®, Rock-
ville, MD, USA). MKN74 cells were maintained in RPMI 
medium 1640 Glutamax I (Gibco) supplemented with 
10% (v/v) fetal bovine serum (FBS, HyClone, Thermo 
Fisher Scientific) and 1% (v/v) Penicillin/Streptomycin 
(Gibco). HeLa and HEK293 cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM, Gibco, Thermo 
Fisher Scientific, Inc, UK) supplemented with 10% (v/v) 
fetal bovine serum (FBS, HyClone, Thermo Fisher Sci-
entific, Inc, UK) and 1% (v/v) Penicillin/Streptomycin 
(Gibco). All cultured cells were maintained at 37 °C in a 
humidified 5%  CO2 incubator and the medium was sub-
stituted every 2–3 days.
LNA anti‑miR design
The selection of the miR-9 target sequence was achieved 
by searching on the database TargetScan v7.1 [29–32]. 
Complementary LNA-based AMOs were designed tak-
ing into consideration optimal sequence length, speci-
ficity to the target, and theoretical melting temperature. 
Two LNA-based AMOs were synthesized with a phos-
phorothioate backbone (PS): an LNA/DNA anti-miR 
oligonucleotide sequence (AM_ LNA_PS) and another 
sequence harboring a 2′O-Methyl substitution (AM_
LNA_2OMe_PS) (Fig.  1a). Additionally, two oligonu-
cleotide sequences were used as a control: a scramble 
LNA sequence similar to the LNA/DNA AMO designed 
with 2 mismatches in the stretch targeting the seed 
region of mR-9 (SC_LNA_PS), and a commercial scram-
ble sequence (SC_LNA_PS*). After the selection of the 
AMOs, a nucleotide alignment with Basic Local Align-
ment Search Tool (BLAST) was performed to ensure 
that the sequences were not targeting a similar region in 
a b
c
Fig. 1 Schematic representation of the strategy applied in this work. a Design of the LNA‑AMOs used in this manuscript. b Uptake and cytotoxic 
assessment of LNA‑AMOs in cancer cell lines by fluorescence in situ hybridization (FISH) and MTT assay, respectively. c Silencing effect of the 
developed AMOs to the target miR‑9 and its consequences on the expression of the E‑cadherin by real‑time PCR and Western blot analysis
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another gene. The theoretical melting temperature  (Tm) 
of the AMO sequences was determined using the avail-
able online platforms, as an indicator of the hybridiza-
tion temperature  (TH). The  Tm predictions for LNA/
DNA sequences were evaluated using the Biophysics 
tool of IDT (available at http://bioph ysics .idtdn a.com/). 
Predictions for the AM_LNA_2OMe_PS sequence were 
determined with the 2′OMeRNA/calculator (available at 
http://rnach emlab .ibch.pozna n.pl/calcu lator 1.php.
LNA anti‑miR synthesis
The oligonucleotide sequences used in this study were 
synthesized at the University of Southern Denmark as 
described elsewhere [33]. Briefly, the oligonucleotides 
were synthesized under anhydrous conditions using 
a standard automated nucleic acid synthesizer (Expe-
dite 8909 instrument, PerSpective Biosystems Inc., MA, 
USA). LNA monomers were commercially available at 
Exiqon (Vedbaek, Denmark), and 2′-OMe were avail-
able at RiboTask ApS (Odense, Denmark). Synthesis was 
performed at the 0.2–1.0  μmol scale using a universal 
polystyrene-based support and the following conditions: 
trichloroacetic acid in  CH2Cl2 (3:97) as detritylation rea-
gent; 0.25  M 4,5-dicyanoimidazole (DCI) in  CH3CN as 
activator; acetic anhydride in THF (9:91, v/v) as cap A 
solution; N-methylimidazole in THF (1:9, v/v) as cap B 
solution; and a thiolation solution containing 0.0225  M 
xanthan hydrate in pyridine/CH3CN (20:90, v/v). Cou-
pling time was 4.6 min for both monomers. Fluorescein 
phosphoramidite (FAM, Glen Research, VA, USA) was 
added in anhydrous acetonitrile (0.1  M) and activated 
by tetrazole with a 20  min coupling time. The stepwise 
coupling yields (95–99% per step) were based on the 
absorbance of the dimethoxytrityl cations (DMT+) 
released after each coupling step. The cleavage from the 
support was carried out by using 98% aqueous metha-
nol/ammonia solution 7 N in methanol (1:1), 2 h at room 
temperature (RT) followed by 32% aqueous ammonia 
solution, 12 h at 55  °C. The oligonucleotides were puri-
fied by reversed-phase HPLC (RP-HPLC) using a Waters 
600 system equipped with an XBridge OST C18 (2.5 μm, 
19 × 100 mm) column and an XBridge Prep C18 (5 μm, 
10 × 10  mm) precolumn. After removal of the DMT-
group, the oligonucleotides were characterized by ion-
exchange HPLC (IE-HPLC) on a Dionex system HPLC 
(VWR) and by matrix-assisted laser desorption ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF) 
on a Microflex Maldi (Bruker instruments, Leipzig, Ger-
many). The purified oligonucleotides were precipitated 
by acetone and their purity (> 90%) and compositions 
were verified by IE-HPLC and MALDI-TOF analysis, 
respectively.
Cellular uptake
Cellular uptake of the FAM_AM_LNA_PS sequence was 
monitored by Fluorescence in  situ hybridization (FISH) 
as described by Guimarães et al. [34] with modifications. 
MKN74 cells were cultured in a 24-well plate until reach-
ing 70% of confluence. Then, the medium was discarded 
and the cells were fixed using a 4% paraformaldehyde 
solution, followed by a fixation with 50% ethanol. Each 
fixation was performed for 10 min at RT. After the fixa-
tion, it was added a hybridization solution containing the 
FAM_AM_LNA_PS at a final concentration of 5, 50 and 
100 nM. Plates were then incubated at 37 °C for 2 h. Two 
types of hybridization solutions were tested: one con-
taining 50% (v/v) formamide (Across Organic, NJ, USA), 
10% (v/v) dextran sulphate (Fisher Scientific, MA, USA), 
0.1% (v/v) Triton-X (Panreac, Barcelona, Spain), 5  mM 
of EDTA disodium salt 2-hydrate (Panreac), 50  mM 
Tris–HCl (Fisher Scientific NJ, USA), 10 mM NaCl (Pan-
reac); and another containing urea (VWR BHD Prolabo, 
Haasrode, Belgium) with different concentrations (0.5 
and 2  M) in 900  mM of NaCl (Panreac). After hybridi-
zation, the solution was discarded and it was added a 
pre-warmed washing solution containing 5  mM Tris 
Base (Fisher Scientific), 15  mM NaCl (Panreac) and 1% 
Triton X (Panreac) for 30 min at 37  °C. Coverslips were 
recovered from the plate and were mounted in a micro-
scopic slide. For each experiment two negative controls 
were made: one using the same hybridization condi-
tions, but without any oligonucleotide sequence in the 
solution, and another containing the scramble sequence 
(FAM_SC_LNA_PS).
For the assay using AMOs directly into the culture 
medium, after the seeding of the MKN74 cells, the 
medium was removed and the hybridization solution 
containing 0.5 M of urea and the FAM_AM_LNA_PS at 
a final concentration of 100  nM was added for 10  min. 
Afterwards, the medium was reestablished and the 
hybridization took place for an additional 2, 4, 8 and 48 h, 
at 37 °C in a 5%  CO2 incubator. Then, cell slides were fix-
ated and washed as described above. The microscopic 
slides were mounted using VECTASHIELD Antifade 
Mounting Medium with DAPI (Vector Laboratories, CA, 
USA). For image acquisition, an AxioImager Z1 (Carl 
Zeiss, Germany) epifluorescence microscope was used 
with a medium grid for optical sections of the fluores-
cent image. The FAM fluorochrome attached to the oli-
gonucleotides was excited at 488 nm wavelength and the 
exposure time was fixed for all the preparations.
Viability assay
The different cell lines were seeded at 1.6 × 105 cells/well 
in 96-well plates and left 24 h to duplicate. Cells were then 
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incubated with different concentrations (0.5–100 nM) of 
LNA-AMOs diluted in Phosphate Buffer Saline 1X (PBS), 
for 24 and 48 h. Cell viability was assessed by MTT (3-(4, 
5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bro-
mide) assay using the CellTiter  96® AQueous One Solu-
tion Cell Proliferation Assay (Promega Corporation, WI, 
USA) according to the manufacturer’s instructions. As 
a negative control, untreated cells exposed to the same 
conditions were used. Experiments were performed in 
triplicate.
Total RNA extraction
Total RNA from each sample was extracted using the 
mirVana™ miRNA isolation kit (Invitrogen, Thermo 
Fisher Scientific, MA, USA), according to the manufac-
turer’s protocol. Shortly, the samples were lysed followed 
by an acid-phenol chloroform extraction. Total RNA was 
collected and small RNAs were purified by precipitation 
with ethanol. Small RNAs were immobilized on glass-
fibre filters, washed and eluted with 30–60 μL of nucle-
ase-free water. RNA yield and purity were determined by 
measuring the absorbance at 260 and 280 wavelengths in 
a  NanoDrop® Spectrophotometer (ND-1000; Fisher Sci-
entific). Absorbance ratios (A260: A280) between 1.8 and 
2.0 were considered optimal.
Reverse transcription
The synthesis of single-stranded cDNA from total RNA 
samples for miRNA amplification was obtained using the 
 TaqMan® MicroRNA Reverse Transcription Kit (Applied 
Biosystems, CA, USA), according to the manufacturer’s 
protocol. In brief, each reaction consisted on 10  ng of 
small RNA, 0.15 μL of dNTP Mix with dTTP (100 mM 
total), 0.19 μL of RNase Inhibitor (20 U/μL), 1.5  μL of 
10 × RT Buffer, 1 μL of Multiscribe™ RT enzyme (50 U/
μL), 3 μL of 5 × RT Primers: hsa-miR-9 (RT 583; Applied 
Biosystems) and RNU48 (RT 001006; Applied Biosys-
tems) and nuclease-free water for a final volume of 15 μL. 
The reaction was performed at 16  °C for 30  min, 42  °C 
for 30 min followed by 85 °C for 5 min. The reverse tran-
scriptase reaction for CDH1 mRNA amplification was 
performed using 200  ng of RNA, 1  μL of random hex-
amer mix (MB129021, Nzytech, Lisbon, Portugal), 1  μL 
of dNTP Mix with dTTP (100 mM total), 1 μL of RNase 
Inhibitor (20 U/μL), 2 μL of 10 × RT Buffer, 1 μL of Mul-
tiscribe™ RT enzyme (50 U/μL) and nuclease-free water 
for a final volume of 20 μL. Each reaction was carried 
on a thermocycler according to the following program: 
10 min at 70 °C, 2 min at 4 °C, and 1 h at 37 °C.
Quantitative real‑time PCR
qRT-PCR was performed for the relative quantification 
of miR-9 and of CDH1 expression, in MKN74 cells after 
treatment with LNA-based AMOs in the conditions 
above. The qRT-PCR reaction for amplification of miR-9 
was performed using the TaqMan MicroRNA Assays 
(TM 000583; Applied Biosystems), according to the 
manufacturer’s procedure. For the amplification of CDH1 
mRNA, 0.5  μl of TaqMan Real-Time probe was used in 
a PCR mixture containing 0.5  μl cDNA, 5.0  μl TaqMan 
2X Universal PCR Master Mix No  AmpErase® UNG 
(Applied Biosystems). Reactions were incubated at 95 °C 
for 10 min followed by 40 cycles at 95 °C for 15 s and at 
60 °C for 1 min and run on an Applied Biosystems 7500 
Fast Real-Time PCR System. Each sample was amplified 
in triplicate. Relative miR-9 expression was normalized 
to levels of RNU48 (TM 001006; Applied Biosystems) 
endogenous control, and relative CDH1 expression was 
normalized to levels of glyceraldehyde 3-phosphate dehy-
drogenase (Human GAPDH Endogenous Control FAM™ 
Dye/MGB Probe, Non-Primer Limited, Applied Biosys-
tems). The Applied Biosystems 7500 Fast software was 
used to analyze the Ct values and the relative amount of 
miRNA and CDH1 mRNA were determined using the  2−
ΔΔCt method.
Western blot analysis
Western blot was performed to analyze the effect LNA-
AMOs on the expression E-cadherin protein, under the 
same conditions stated above for the qRT-PCR analy-
sis. MKN74 cells, treated or not with LNA-AMOs were 
washed three times with ice-cold PBS, and then dis-
rupted using a lysing buffer, containing 1% Triton X-100 
(v/v), 1% NP-40 (v/v, pH 7.4), supplemented with phos-
phatase inhibitor (1: 100) and protease inhibitor (1: 7) 
during 15  min. Samples were further centrifuged at 
14,000 rpm for 20 min at 4 °C and the supernatants col-
lected. 20  μg of total protein were mixed with laemmli 
4x (Bio-rad, CA, USA), denatured at 95 °C for 5 min, and 
separated on a 10% polyacrylamide gel. Proteins were 
then transferred onto a nitrocellulose membrane and the 
membranes were blocked 30 min at RT with 5% dry milk 
in 0.5% Tween-PBS, followed by incubation at RT dur-
ing 2  h with the antibodies in the following dilutions: a 
mouse monoclonal anti-α-E-Cadherin antibody (1: 1000) 
(Clone 36/E-Cadherin, BD Biosciences, CA, USA), and 
a mouse anti-α-GAPDH antibody (1: 30,000) (sc-47724, 
Santa Cruz Biotechnology, TX, USA). Blots were then 
washed 3 times with 0.5% PBS-Tween and incubated with 
a secondary anti-mouse antibody (1: 20,000) (sc-516102, 
Santa Cruz Biotechnology) for 2 h at RT.
Image quantification
FISH images were analyzed using the ImageJ software 
(National Institutes of Health, MD, USA). Data was 
plotted as mean of arbitrary fluorescence units (AFU), 
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representing the difference between the mean of fluores-
cence intensity of each sample and the background inten-
sity values. Western Blot images were analyzed using the 
Quantity  One® 1-D software v4.6.6 (Bio-rad), and data 
was normalized to an endogenous control (GAPDH). The 
background values were obtained by measuring a blank 
region from each FISH and Western Blot image.
Statistical analysis
All data are expressed as mean ± standard deviation. 
Each experiment was repeated at least 3 times. Statisti-
cal significance was determined using  GraphPad® Prism 
software v5.0.3. FISH results were analyzed using one-
way analysis of variance (ANOVA) and Tukey’s multi-
ple comparisons test. MTT, qRT.PCR, and Western Blot 
results were analyzed using two-way ANOVA and Tuk-
ey’s multiple comparisons test. Differences in data values 
were considered significant at p values lower than 0.05 
(***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05).
Results
Anti‑miR oligonucleotides design and synthesis
Two LNA-based AMO sequences were designed with 
16 nucleotides targeting specifically the miR-9 region 
responsible for CDH1 dysregulation (AM_LNA_PS and 
AM_LNA_2OMe, Table  1). The AM_LNA_PS sequence 
is a DNA sequence with an LNA substitution in every 
2 nucleotides, and the AM_LNA_2OMe, in addition 
to the LNA substitutions, contains 2′-OMe monomers 
along the sequence. AMOs harboring LNA modifica-
tions have been reported to show high thermal stability, 
resistance to nucleases and high efficiency on silencing 
miRNAs [23, 35, 36]. LNA substitutions combined with 
2′-OMe modifications are known to further improve 
binding affinity when compared to oligonucleotides with 
only one type of substitution [37]. Additionally, two con-
trol sequences were synthesized, one designed to display 
two mismatches at the seed region (SC_LNA_PS), and 
the other is a scramble sequence with 19 nucleotides 
(SC_LNA_PS*) available commercially. Furthermore, 
the AM_LNA_PS and the scramble SC_LNA_PS were 
labeled with FAM (FAM_AM_LNA_PS and FAM_SC_
LNA_PS, respectively, Table  1) for cellular uptake and 
viability assays. All sequences were designed with a 
PS backbone, which is reported to have increased anti-
miRNA activity and enhanced cellular uptake compared 
to non-modified phosphodiester bonds (PO) [38].
The substitution of DNA nucleotides by LNA mono-
mers increases the predicted melting temperature of 
the sequences. Therefore, we determined the possible 
minimum length for AMOs that did not match addi-
tional off-targets and that kept a melting temperature 
value allowing the hybridization around 37  °C. Since 
there are no mathematical models to predict the  TH for 
these type of oligonucleotides,  Tm values were predicted 
instead (Table  1), which are generally 15–30  °C higher 
than the  TH [39]. For that reason, the AMO sequences 
were designed in order to display a  Tm ranging from 50 to 
70 °C (Table 1).
Screening of the cell lines for miR‑9 content
The cell lines used in this study were first tested by qRT-
PCR to assess their miR-9 expression levels (Fig.  2a). 
Moreover, since it is expected that miR-9 antagonists 
induce re-expression of E-cadherin, the expression of 
E-cadherin expression level was also assessed by west-
ern blot (Fig. 2b). With exception of the MTT assay, the 
Table 1 AMO designs used in this work and respective theoretical melting temperatures
LNA nucleotide monomers are represented by the symbol “+” before the letter, 2′-OMe-RNA monomers in small caps letters, DNA nucleotides in capital letters, and 
FAM—fluorescein; the symbol asterisk refers to the scramble sequence available commercially
Length (nt) Name Type Sequence (5′‑3′) Predicted  Tm (°C)
16 AM_ LNA_PS LNA/DNA GC+TAG+ATA+ACC+AAA+GA 57.92
16 AM_LNA_2OMe_PS 2′‑OMe/LNA gc+Uag+Aua+Acc+Aaa+Ga 77.60
16 SC_LNA_PS LNA/DNA GC+TAG+ATA+AGC+TAA+GA 51.95
19 SC_LNA_PS* LNA/DNA TAA+CAC+GTCT+ATAC+GCC+CA 61.03
16 FAM_AM_ LNA_PS LNA/DNA FAM_GC+TAG+ATA+ACC+AAA+GA 57.92
16 FAM_SC_LNA_PS LNA/DNA FAM_GC+TAG+ATA+AGC+TAA+GA 51.95
a b
Fig. 2 Expression profile of the cell lines used in this study. a Mir‑9 
expression assessed by qRT‑PCR and b E‑cadherin expression 
visualized by Western blot analysis
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following experiments were performed using MKN74 
cells, since this cell line expresses both miR-9 and E-cad-
herin (Fig.  2). This cell line while not presenting a high 
content on miR-9 expression when compared to other 
gastric cancer cell models [40], it presents an unaltered 
E-cadherin expression, and for that reason it was cho-
sen for this study. In the cell viability studies, all cell lines 
were used, regardless of miR-9 and E-cadherin expres-
sion, to test the cytotoxic effect of AMOs in different 
tumor cell-types.
Cellular uptake of AMOs and their effect on cell viability
After designing the AMOs, we investigated their ability 
to enter cancer cells. For that, the cellular uptake of the 
FAM_AM_LNA_PS oligonucleotide was monitored by 
FISH using the miR-9-positive MKN74 cell line.
The first FISH protocol tested comprehended a hybrid-
ization solution containing, among other components, 
30% formamide as a destabilizing agent. However, it 
was not possible to visualize a fluorescence signal, even 
when protocol adjustments, such as hybridization, wash-
ing, and fixation time were made (data not shown). As an 
alternative strategy to formamide, a hybridization buffer 
containing urea was used for the subsequent FISH assays.
Using urea in the hybridization solution, fluorescence 
signals were detected for all tested concentrations (FAM_
AM_LNA_PS at 5, 50 and 100 nM, Fig. 3a), with signifi-
cantly higher intensities at concentrations of 50 nM and 
100 nM (Fig. 3b). As expected, the negative control, i.e. 
cells without treatment with AMOs, did not display any 
fluorescent signal (control, Fig. 3a).
The FAM_SC_LNA_PS was used as another negative 
control at a 50  nM concentration. This concentration 
was selected based on the results with FAM_AM_LNA_
PS, which showed no statistically significant differences 
between concentrations of 50 nM and 100 nM (Fig. 3b). 
Using the same FISH settings, the FAM_SC_LNA_PS 
showed a fluorescence signal in the same range of the 
lowest FAM_AM_LNA_PS concentration (5 nM, Fig. 3b 
and 3c). In order to improve AMOs specificity and 
to eliminate off-target signal, the FISH protocol was 
adjusted for a longer washing time and and/or higher 
urea concentration. An extended washing step (Fig.  3a, 
SC_LNA_PS/0.5M_60 min) was sufficient to increase the 
hybridization stringency and reduce the FAM_SC_LNA_
PS signal (Fig. 3c).
To further investigate the cellular uptake of AMOs in a 
setting without carriers or transfection agents, the FAM_
AM_LNA_PS and correspondent scramble sequence 
were added directly in the culture medium. Remark-
ably, a positive fluorescence signal was observed as early 
as 2  h after the AMOs addition (FAM_AM_LNA_PS/
naked_2 h, Fig. 3d). Furthermore, the fluorescence signal 
was detected at all time-points, even after 48 h of incuba-
tion (FAM_AM_LNA_PS/naked_48 h, Fig. 3d). Although 
the signal was not observed transversely in all the cells, 
it was still possible to detect fluorescence and to demon-
strate that LNA-based AMOs are able to endure in the 
medium for long periods. Moreover, the LNA-AMOs 
were able to bind the target miR-9 in the absence of dena-
turant agents or carriers.
AMOs effect on cell‑lines viability
After confirming the cellular uptake of the LNA-based 
AMOs, the effect of AMOs in cell viability was assessed 
in a panel of cell lines. It was decided to use the sequences 
labeled with FAM to further evaluate the effect of the flu-
orochrome in the cell viability. MTT assay results showed 
that, up to a concentration of 100 nM, FAM_AM_LNA_
PS did not significantly reduce cell viability in any of the 
cell line models used (Fig. 4a). These results suggest that 
LNA-based AMOs are not cytotoxic.
The MTT test was also performed using the FAM_
SC_LNA_PS sequence at 5  nM and 100  nM for 24 and 
48 h. Since the FAM_AM_LNA_PS did not show signifi-
cant cytotoxic effect in vitro, we tested the effect of the 
scramble sequence on cell viability only for the mini-
mum and maximum values of concentration used for the 
FAM_AM_LNA_PS. The FAM_SC_LNA_PS also did not 
significantly compromise cell viability (Fig. 3b), reinforc-
ing that LNA-based AMOs are not cytotoxic. Moreover, 
since both sequences were labeled with FAM and both 
did not significantly reduced cell viability, this labelling 
was also considered not cytotoxic.
Fig. 3 Cellular uptake assay of the labeled AMOs using MKN74 cells. a Representative epifluorescence microscopy images obtained with 
FAM_AM_LNA_PS at different concentrations (FAM_AM_LNA_PS/5 nM,/50 nM and/100 nM) in a hybridization solution containing 0.5 M of urea. 
The hybridization step was performed at 37 °C for 2 h, followed by 30 min of washing. As negative controls, cells without any sequence (control) 
or incubated with FAM_SC_LNA_PS were used. The FAM_SC_LNA_PS/0.5M_30 min, and FAM_SC_LNA_PS/0.5M_60 min corresponds to the 
FISH assay using the FAM_SC_LNA_PS hybridized for 2 h using a solution containing 0.5 M of urea, followed by a washing step of 30 and 60 min, 
respectively. All images were acquired using an ×200 magnification. b Average fluorescence intensity for the FAM_AM_LNA_PS at 5, 50, and 
100 nM; and c for the FAM_SC_LNA_PS using different concentrations of urea in the hybridization solution and washing times. Fluorescent signal 
intensity is expressed in arbitrary fluorescent units (AFU); ns—not significantly different from control (p > 0.05). d Cellular uptake assay using the 
FAM_AM_LNA_PS at 100 nM (FAM_AM_LNA_PS/naked) applied directly into the medium after 2 and 48 h of hybridization. DAPI was used to stain 
the nucleus. The image was acquired using an ×400 magnification
(See figure on next page.)
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Effects of AMOs in the expression of miR‑9 
and of E‑cadherin
The AM_LNA_PS and another chemically-modified 
oligonucleotide (Table  1) were used for evaluating the 
effectiveness of AMOs on the silencing of miR-9.
The SC_LNA_PS sequence had no effect in the 
expression of miR-9, presenting similar results to the 
SC_LNA_PS* sequence (data not shown), and was thus 
suitable to function as a negative control.
The AM_LNA_PS significantly decreased the miR-9 
expression in the first 8  h of incubation. After that 
time-point, cells started to recover miR-9 content until 
basal levels (Fig.  5a). On the other hand, the CDH1 
mRNA twofold variation showed a significant increase 
after 4  h of incubation, probably as a response to the 
decrease on miR-9 expression at the same time-point. 
After that, a decrease on CDH1 expression is observed, 
before its stabilization to basal levels (Fig. 5b).
The AM_LNA_2OMe_PS influenced the expres-
sion of miR-9 during a longer period. A decrease of 
miR-9 expression levels was visible after 4  h, which 
was maintained up to 12 h of incubation (Fig. 5a). After 
that point, there was an increase of miR-9 expression 
levels until the basal miRNA level. In terms of CDH1 
mRNA expression, with the exception of the 4 h time-
point, there is no significant increase on CDH1 mRNA 
relative expression, despite the significant decrease in 
miR-9 expression (Fig. 5b).
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Fig. 4 MTT viability assay results for the different cell lines MKN74, HeLa and HEK293. a Cell lines treated with FAM_AM_LNA_PS and with b FAM_
SC_LNA_PS. The control is related to the cells without any AMOs treatment
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When analyzing the results by western blot (Fig. 5c), in 
all the situations it is evident an effect on the E-cadherin 
expression in comparison with the control. In the cells 
treated with the AM_LNA_PS, there is a slight increase 
in E-cadherin expression after 8  h of incubation, which 
then remains stable in the following time points. These 
results are in accordance with the qRT-PCR data, with a 
small delay between the CDH1 mRNA relative content 
and the consequent effect on the protein expression 
(Fig.  5b, c). In cells treated with the AM_LNA_2OMe_
PS, the levels of E-cadherin increased at all time points, 
especially at 8 and 12  h, where a significant increase of 
protein expression was observed (Fig. 5c).
Discussion
Overexpressed miRNAs are often associated with the 
downregulation of many tumor suppressing proteins, 
and thus being implicated in the pathogenesis of sev-
eral human diseases, including cancer. In GC, miR-9 has 
been reported to be mainly downregulated, functioning 
as a tumor suppressor by targeting RAB34 (encoding 
the Ras-related protein RAB-34) and NFKB1 (encod-
ing the NF-kappa-B transcription factor) oncogenes [41, 
42]. However, miR-9 has also been shown to be upregu-
lated in GC, where its overexpression leads to the down-
regulation of the CDX2 gene, which encodes a human 
caudal-type homeobox protein, CDX-2, promoting cell 
proliferation and invasion [40].
In humans, miR-9 can be transcribed from three inde-
pendent genomic loci, resulting in three pri-miRNAs 
(miR-9-1, miR-9-2 and miR-9-3). Those three pri-miR-
NAs can be further processed to give rise to two func-
tional mature miRNAs: miR-9-3p and miR-9-5p, being 
the later the most investigated mature miR-9. The expres-
sion levels of miR-9-5p are highly variable across cancers, 
being either upregulated or downregulated. Also, it has 
been shown that the same miRNA gene can behave as 
oncogene or tumor suppressor gene in the same type of 
cancer, depending on the type of alteration, cell type or 
transcriptional/posttranscriptional events. Due to their 
small size, point mutations are less probable to occur, and 
the main mechanisms for miRNA inactivation or activa-
tion seem to be correlated with homozygous deletions, 
the combination mutation plus promoter hypermethyla-
tion (in case of miRNA inactivation/underexpression) or 
gene amplification (in case of miRNA activation/over-
expression). Due to the accumulating evidence of miR-9 
overexpression in a panel of 37 GC specimens, and that 
its overexpression might influence the expression of 
E-cadherin, the AMOs developed in here were designed 
to specifically bind to the miR-9-5p region that targets 
the CDH1 3′UTR mRNA.
Before moving to a treatment based approach, the abil-
ity of AMOs to provide a fluorescence signal that can be 
used as a diagnostic marker was evaluated. Herein, after 
optimization of a standard FISH protocol, it was possi-
ble to detect a specific FISH signal using the FAM_LNA_
PS at 50  nM in a hybridization buffer containing urea 
instead of formamide. Formamide has been extensively 
used for over 30  years as an RNA stabilizer to reduce 
incubation temperature and/or heterologous background 
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the relative variation of E‑cadherin expression in MKN74 cells after 
treatment with LNA‑anti‑miR oligonucleotides and the control, 
MKN74 cells without any treatment, at the same time‑points used for 
qRT‑PCR. All the qRT‑PCR and western blot results were normalized 
against the MKN74 control and the levels of the respective 
endogenous control (RNU48 for miR‑9 and GAPDH for CDH1 gene 
quantified by qRT‑PCR and E‑cadherin protein expression by western 
blot)
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hybridization that often occurs with RNA probes [43]. 
Even though its advantageous hybridization features, 
formamide is very toxic and one of the most hazardous 
chemicals identified by regulatory agencies [44]. Probably 
due to the high toxicity profile, the in vitro models could 
not endure the FISH treatment, leading to an unsuccess-
ful hybridization of the AMOs used in this study. Several 
studies report the use of urea in hybridization solution 
as an alternative to formamide [45–47]. Hybridization 
buffers containing urea are less toxic and enclose far 
less chemical compounds comparing to the ones with 
formamide [48]. The urea-based hybridization solution 
has provided a strong and specific fluorescence signal, 
especially when combined with longer washing periods 
(60 min).
Additionally, the ability of AMOs to diffuse through the 
cell membrane and bind to the miRNA in the absent of a 
carrier or a denaturant solution was evaluated by adding 
AMO directly to the culture media. Fluorescence signal 
was observed as soon as after 2 h of incubation with the 
AM_LNA_PS sequence. PS-oligonucleotides targeting 
miRNAs have been shown to be rapidly internalized by 
cells, both in vitro and in vivo, in the absence of any car-
riers, and to interfere with miRNA activity in a process 
called Gymnosis [49, 50]. Gymnotic studies, however, 
tend to use higher concentrations of AMOs for longer 
periods of time [49, 51]. From our study, LNA-based 
AMOs are able to enter the cells without any carriers or 
transfection agents and to specifically bind and inhibit 
miR-9 expression. Further tests on cellular viability have 
shown that AMOs were not toxic to any of the three cell-
lines tested.
Moreover, the LNA-AMOs tested here were able to 
repress the miR-9 expression at early time points and 
at a low concentration. There is evidence that the PS-
AMOs internalization occurs via the endosomal path-
way, through which the oligonucleotides might meet 
the miRNA within, blocking its action [51]. This silenc-
ing mechanism is still not yet validated for all cell types 
and miRNAs. Nevertheless, it seems that the PS-AMOs 
do not necessarily need to be released from endosomes 
to act upon their target miRNA. This mechanism might 
explain the fact that the AMOs tested in this study were 
able to silence the target miRNA in such a short period 
of time.
LNA-modified AMOs have been reported to specifi-
cally inhibit miRNAs leading to the up-regulation of the 
target proteins [25, 26, 35, 37]. The 2′OMe modification 
associated with LNA monomers is known to display 
increased potency and stability on silencing aberrant 
miRNAs [52]. Accordingly, the AM_LNA_2OMe_PS 
used herein showed a more extensive effect on repressing 
miR-9 levels, when compared with the other design.
Overall, for the AMOs tested, it was not visible an 
inversely proportional variation on CDH1 mRNA relative 
expression level as a possible consequence of the miR-9 
silencing. The slight increase in the CDH1 mRNA expres-
sion level along time could be explained by the fact that 
we only tested a low-dose of AMOs and in a relatively 
short period of time. Also, the AMOs tested, despite 
designed to target specifically the miR-9 loci believed 
to promote E-cadherin impairment, they might target 
other miR-9 precursors. As a consequence, the decrease 
of miR-9 content might be more extensive than the effect 
on the CDH1 mRNA expression level. Another factor to 
have in consideration is that at this early stage we believe 
the AMOs only meet the miRNA in the endosomes, and 
probably due to this do not reach all the available miR-9 
available. Therefore, the AMOs presented in here might 
present higher potency on silencing the target miRNA in 
a setting using a broader delivery system, higher AMO 
concentrations and/or longer incubation periods.
Regarding the protein expression, it was observed a 
delay between the effect on the relative content of CDH1 
mRNA and the consequent impact on the protein expres-
sion, due to the normal time-gap between mRNA re-
expression and initiation of the protein translation. The 
AMOs tested have roughly followed the same pattern 
between the results obtained by mRNA qRT-PCR and 
protein quantification. For the AM_LNA_PS, after 8  h 
of incubation there is a noteworthy decrease on CDH1 
mRNA expression. The reason for this result is not very 
clear. We hypothesize that due to the tight regulation 
system of the MKN74 cells, as the cellular machinery is 
trying to regain miR-9 function, probably by overproduc-
ing the miRNA to compensate the effect of the anti-miR 
sequence, it might have destabilized the expression of 
CDH1 mRNA.
The therapeutics involving AMOs is a promis-
ing approach towards an effective treatment of sev-
eral human pathologies caused by the dysregulation 
of miRNAs. Currently, three LNA-AMO-based drugs 
are undergoing clinical trials: one called Miravirsen 
developed by Santaris Pharma to control the activity of 
miR-122 associated with Hepatitis C virus (HCV) infec-
tion [53]; and two others from miRagen Therapeutics to 
inhibit miR-155 (MRG-106) and miR-92a (MRG-110, 
S95010) involved respectively, in blood cancers and in 
acute cardiovascular diseases. Despite of the promising 
results, no therapeutic strategy has been yet fully devel-
oped and validated. The AMO technology can also be 
further associated with emerging methodologies for real-
time detection of miRNAs in humans. In  situ detection 
of miRNA accumulation in tumor biopsies may provide 
a highly valuable approach for prognostic and diagnos-
tic evaluation in a clinical setting. In addition, little is 
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still known on how the biological systems regulate miR-
NAs expression in the different human diseases [54]. The 
double role of miRNAs requires a more intense study in 
order to develop reliable, specific and safe technologies 
to fully control miRNA expression. AMOs are indeed a 
great tool, not only for the detection and therapeutics, 
but also for applications that help to unravel the mecha-
nisms behind miRNA biogenesis and function.
Conclusions
A quite straightforward approach to target aberrant 
miRNAs is to develop molecules that specifically binds 
to the target miRNA, blocking its function. In this case, 
by targeting overexpressed miR-9 in GC cell lines using 
AMOs, it was expected to promote the normal function 
of CDH1-encoding mRNA and this way reestablish the 
expression of E-cadherin. In addition to the therapeutic 
approach, this study also aimed to explore the potential 
of AMOs combined with the FISH technology to effec-
tively detect in  vitro overexpressed miRNAs and their 
relevance to function as miRNA markers involved in dif-
ferent human diseases.
In here, we have demonstrated the potential of naked 
LNA-based AMOs to enter cells using low AMO con-
centrations in a relatively short period of action. Moreo-
ver, all the sequences were able to silence the expression 
of upregulated miR-9 using a cancer cell model. Even 
though the results on the E-cadherin expression were not 
so straightforward, there is a slight increase on protein 
expression. Overall, the LNA_2OMe_PS oligonucleotide 
sequence seems to be the design with more promising 
results on the silencing of miR-9.
Furthermore, the designed AMOs might present higher 
potency on silencing the target miRNA in a setting using 
a broader delivery system, higher AMOs concentration 
and/or longer incubation periods. Also, these sequences 
could be further improved and modified to target other 
overexpressed miRNAs within GC and in other human 
disorders.
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